Effects of glycaemic management on diabetic kidney disease

Table 2 Renal end points in observational post-randomisation trials of intensive glucose control in type 1 and type 2 diabetes

	DCCT/EDIC	ADVANCE ON
Diabetes type	1	2
n	1375	8494
Impaired eGFR (HR or RR)	0.63a (0.10-0.55)	N/A
Impaired eGFR or death (HR or RR)	0.5a (0.18-0.69)	N/A
ESKD (HR or RR)	0.49 (-0.14-0.79)	0.54a (0.34-0.85)
ESKD or renal death (HR or RR)	0.63 (0.10-0.55)	N/A

^aSignificant reduction with intensive glucose control. DCCT/EDIC: Diabetes control and complications trial/epidemiology of diabetes and interventions and complications; ADVANCE: Action in diabetes and vascular disease: Pretrex and diamicron MR controlled evaluation; eGFR: Estimated glomerular filtration rate; ESKD: End stage kidney disease; HR: Hazard ratio; RR: Relative risk; N/A: Not available.